- Biden Administration to Back Lifting of COVID Vaccine Patents
- Health Highlights: May 6, 2021
- When Black Americans Encounter Police Violence, High Anxiety Often Follows
- Real-World Studies Show Pfizer Vaccine Shields Against COVID Variants
- Drug Saxenda Aids Weight Loss — But You Should Exercise, Too
- Israel Study: Pfizer Vaccine Gives 95% Protection Against Illness, Hospitalization & Death
- Better Access to Birth Control Boosts School Graduation Rates
- What Was Antarctic Explorer Ernest Shackleton’s Mystery Illness?
- Many Consumers Misunderstand Those ‘Best Before’ Food Labels
- U.S. COVID Outlook Shows Big Improvement by July
Heartburn Drug Kapidex Renamed to Dexilant
THURSDAY, March 4Kapidex (dexlansoprazole) has been given the new name Dexilant — so approved by the U.S. Food and Drug Administration — to avoid confusion with other drugs that have similar names.
There is no problem with Kapidex itself and, other than the name switch, nothing else will be changed about the drug, the FDA said. It’s a proton pump inhibitor, used to treat heartburn and other conditions caused by excess stomach acid.
In a news release, the FDA cited pharmacy errors in dispensing Kapidex, approved in January 2009, citing confusion with the drugs Casodex and Kadian. All three drugs have widely different uses; Casodex is prescribed for prostate cancer and Kadian to treat pain.
The newly named heartburn drug will begin appearing on store shelves in late April, the FDA said. It’s manufactured by Takeda Pharmaceuticals North America.
More information
The FDA has more about this drug’s approval history.
Source: HealthDay
